New combo therapy shows promise for rare gut tumors
NCT ID NCT05249114
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new two-drug combination for people with advanced neuroendocrine tumors (NETs) that have stopped responding to standard treatments. The drugs are cabozantinib (a targeted therapy pill) and Lu-177 DOTATATE (a radioactive treatment that seeks out tumor cells). The main goal is to find the safest dose of cabozantinib when given with the standard dose of Lu-177 DOTATATE. Only 6 participants were enrolled, and the study is no longer recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Providence Portland Cancer Institute - Franz Clinic
Portland, Oregon, 97213, United States